GenScript ProBio announced that it has received $220,000,000 in its Series C round of funding led by Legend Capital Management Co., Ltd. on January 18, 2023. The transaction included participation from HighLight Capital, GF Xinde Investment Management Co., Ltd, GL Ventures, Xiamen C&D Inc., Shanghai New Alliance Investment Management Co., Ltd., Huatai Zijin Investment Co. Ltd and China Industrial International Trust Asset Management Limited.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.65 CNY | +2.11% | +4.82% | +10.59% |
04-30 | Xiamen C&D's Q1 Profit Falls 24% | MT |
04-29 | Xiamen C&D Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.59% | 4.33B | |
+50.57% | 88.36B | |
+47.57% | 74.5B | |
+23.67% | 65.22B | |
+7.15% | 41.46B | |
+35.08% | 32.37B | |
+35.11% | 32.04B | |
+15.90% | 21.52B | |
+15.83% | 17.09B | |
+33.25% | 5.86B |
- Stock Market
- Equities
- 600153 Stock
- News Xiamen C&D Inc.
- GenScript ProBio announced that it has received $220 million in funding from a group of investors